drugset / Trial / NCT02452801

Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function

NCT02452801

Phase 1 Completed 40 enrolled Alkermes, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the effect of various degrees of hepatic function on the pharmacokinetics and safety of ALKS 5461.

Timeline

Start
2015-05
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ALKS 5461 Unknown Oral

Indications

No indication recorded.